Losartan Potassium Tablet
Product Images NDC 72162-2508

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 72162-2508). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (F205834f 7a27 4968 9605 90a2c53ce7e9 01)

Chemical structure of Losartan Potassium. The diagram shows the molecular arrangement including a biphenyl group, tetrazole ring, chlorine, hydroxyl, and potassium ion features characteristic of Losartan Potassium.*

FDA Label Image

Figure 1 (F205834f 7a27 4968 9605 90a2c53ce7e9 02)

A line graph comparing the percentage of patients with a primary endpoint over a 66-month study period between Losartan Potassium (solid line) and Atenolol (dotted line). The graph highlights an adjusted risk reduction of 13% for Losartan Potassium with a p-value of 0.021.*

FDA Label Image

Figure 2 (F205834f 7a27 4968 9605 90a2c53ce7e9 03)

A line graph comparing the percentage of patients with fatal or non-fatal stroke over a study period in months. The graph features two lines representing Atenolol (dotted line) and Losartan potassium (solid line), showing a lower percentage of stroke events in patients treated with Losartan potassium. The graph notes an adjusted risk reduction of 25% with a p-value of 0.001.*

FDA Label Image

Figure 3 (F205834f 7a27 4968 9605 90a2c53ce7e9 04)

A forest plot chart comparing event rates of Losartan Potassium and Atenolol across different patient subgroups. It displays hazard ratios with 95% confidence intervals for two outcomes: primary composite and stroke (fatal/non-fatal). Subgroups include age, gender, race, ischemic heart disease (ISH), diabetes, and cardiovascular disease history.*

FDA Label Image

Figure 4 (F205834f 7a27 4968 9605 90a2c53ce7e9 05)

A line chart comparing the percentage of patients with events over 48 months between Losartan Potassium and placebo groups. The x-axis represents months, and the y-axis shows the percentage of patients with events. The chart notes a risk reduction of 16.1% with Losartan Potassium compared to placebo.*

FDA Label Image

Image (F205834f 7a27 4968 9605 90a2c53ce7e9 06)

FDA Label Image

Company Logo (F205834f 7a27 4968 9605 90a2c53ce7e9 07)

FDA Label Image

Label (Lbl721622508)

Losartan Potassium Tablets, USP 100 mg oral tablets in a repackaged label format. The label includes dosage strength (100 mg), package quantity (30 tablets), NDC number 72162-2508-3, and instructions to scan the package insert QR code for dosage and patient information. Repackaged by Bryant Ranch Prepack and manufactured by Unichem Laboratories Ltd. Storage instructions and warnings to keep out of reach of children are also present.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.